Loading the section…

NAGE: financial statements from SEC — TradeAlmanac

NAGE

Niagen Bioscience, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	31M	34M	31M	30M	26M	23M
Cost of revenue	11M	12M	11M	11M	9M	9M
Gross profit	20M	22M	20M	19M	16M	14M
Research and development	1M	2M	2M	1M	1M	1M
Selling, general and administrative	7M	7M	7M	5M	6M	6M
Operating expenses	18M	18M	17M	15M	15M	14M
Operating income	2M	4M	3M	5M	2M	−256,000
Pre-tax income	7M	5M	4M	5M	2M	−15,000
Income tax	417,000	222,000	128,000	168,000	0	0
Net income	6M	5M	4M	5M	2M	−15,000
Earnings per share	0.08	0.06	0.05	0.07	0.02	0.00
Earnings per share, diluted	0.07	0.05	0.04	0.06	0.02	0.00
Weighted average shares	80M	80M	79M	78M	76M	76M
Weighted average shares, diluted	85M	87M	86M	83M	78M	76M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	67M	65M	64M	60M	56M	45M	32M	28M
Receivables	13M	10M	9M

Cash flow

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Operating cash flow	−1M	—	—	8M	—	—
Depreciation and amortisation	116,000	—	—	158,000

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator